Krystal Biotech, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Krystal Biotech, Inc. (KRYS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $71.55 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $44.79, a 47.55% decline year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $85.39, a 38.80% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $61.52, a 14.90% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $53.54, a 43.39% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $73.02, a 18.50% increase from fiscal 2024.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $61.62, a 5.97% increase from fiscal 2023.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $58.15, a 15.22% increase from fiscal 2022.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $50.47, a 32.40% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $71.55 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $44.79 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $73.02 10-K · filed 2026-02-17 | |||
| 2025-09-30 | $68.04 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $71.56 10-Q · filed 2026-08-03 | |||
| 2025-03-31 | $85.39 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | $61.62 10-K · filed 2026-02-17 | |||
| 2024-09-30 | $61.27 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | $60.33 10-Q · filed 2025-08-04 | |||
| 2024-03-31 | $61.52 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $58.15 10-K · filed 2025-02-19 | |||
| 2023-09-30 | $57.98 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | $56.41 10-Q · filed 2024-08-05 | |||
| 2023-03-31 | $53.54 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $50.47 10-K · filed 2024-02-26 | |||
| 2022-09-30 | $46.28 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $44.13 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $37.34 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $38.12 10-K · filed 2023-02-27 | |||
| 2021-09-30 | $38.11 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $21.41 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $21.93 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $10.45 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $9.43 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $12.48 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $14.22 10-Q · filed 2020-05-04 | |||
| 2019-12-31 | $6.08 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $5.35 10-Q · filed 2019-11-04 | |||
| 2019-06-30 | $3.43 10-Q · filed 2019-08-05 | |||
| 2019-03-31 | $2.75 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $2.46 10-K · filed 2020-03-10 | |||
| 2018-09-30 | $2.46 10-Q · filed 2018-11-05 | |||
| 2018-06-30 | $2.46 10-Q · filed 2018-08-06 | |||
| 2018-03-31 | $2.46 10-Q · filed 2018-05-07 | |||
| 2017-12-31 | $0.00 10-K · filed 2018-03-12 | |||
| 2017-09-30 | $0.00 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |